Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessSingle cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
Originally described as interpatient variability, tumour heterogeneity has now been demonstrated to occur intrapatiently, within the same lesion, or in different lesions of the same patient. Tumour heterogenei...
-
Article
Open AccessReprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF ...
-
Article
Open AccessImmunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
-
Article
Open AccessImmunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts